MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has ...
A new study has found a potential breakthrough in the treatment of chronic pain and doesn't rely on addictive opiate ...
Scientists at the University of Leeds have discovered a new way to tackle chronic pain, which could offer hope to the 28 ...
In a small clinical study, researchers in the US examined the nature of new-onset pain reported by people with long COVID and explored potential associations between long COVID symptoms and pain.
Chronic pain can have huge impacts on patients and their families. We discuss its prevalence and emerging therapies with Asal ...
Peripheral neuropathy is a condition that affects the nerves outside the brain and spinal cord. It can cause pain, tingling, ...
A major breakthrough in our understanding of pain has been revealed in a collaborative study led by a Leeds scientist, ...
A team of researchers from Weill Cornell Medicine and the Burke Neurological Institute has developed a groundbreaking drug ...
A summary of the joint Annual Scientific Meeting (ASM) of the Irish Pain Society (IPS) and Northern Ireland Pain Society ...
By demonstrating Ketamir-2's robust safety profile in comprehensive preclinical studies, MIRA has significantly de-risked this critical aspect of drug development. This milestone positions the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback